Presentation at BIO CEO & Investor Conference in New York February 9th, 2009
Published 09.02.2009
Dr Sven Rohmann presented Biotec Pharmacon at the 11th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 9th, 2009, 11:00 local time. ...
Favourable ruling for Biotec Pharmacon in U.S patent case
Published 30.01.2009
A decision by the U.S district court judge in Minnesota on January 28 largely rules in Biotec Pharmacon's favour in the patent infringement suit brought by Biopolymer Engineering, ...
Biotec Pharmacon is experiencing a faster than expected patient enrolment in the second of its two phase III studies with SBG for treatment of diabetic ulcers. However, the oral mu...
Started Cod-UNG deliveries to Siemens Healthcare Diagnostics
Published 17.12.2008
Biotec Pharmacon ASA has started deliveries of Cod-UNG enzyme to Siemens Healthcare Diagnostics, who will use the enzyme in a new diagnostic product for quantification of HIV-1....
Diabetic Ulcers: Phase III program continues as planned after interim analysis
Published 21.11.2008
Results from a blinded interim analysis did not prompt Biotec Pharmacon to make any changes to the sample size of its phase III study with SBG (soluble beta-glucan) for treatment o...
Patient inclusion started in second phase III diabetic ulcer study
Published 04.11.2008
The first 3 patients have been enrolled in the second of Biotec Pharmacon’s two phase III-studies with SBG for treatment of diabetic ulcers. An estimated 3.5 million diabetes patie...
Patient inclusion started in phase III Oral Mucositis study
Published 16.10.2008
Patient inclusion has commenced as planned in the first of two phase III studies for the use of Biotec Pharmacon’s SBG in patients with oral mucositis. This is a common and potenti...
Dr. Sven Rohmann (46) joins Biotec Pharmacon ASA as Vice President Business Development.
Published 01.10.2008
Dr. Rohmann is a MD by training and has a Ph.D. in experimental cardiology. He is joining the company from Novartis Pharma AG, where he had different responsibilities within the Gl...
Biotec Pharmacon ASA selger Immunocorp Animal Health AS
Published 28.08.2008
Det er tidligere informert om at Biotec Pharmacon den 22. august inngikk avtale om salg av sitt heleide datterselskap Immunocorp Animal Health AS til det brasilianske selskapet Bio...
Biotec Pharmacon rendyrker bio-farmasøytisk virksomhet - selger Immunocorp Animal Health
Published 25.08.2008
Biotec Pharmacon ASA har inngått avtale om salg av det heleide datterselskapet Immunocorp Animal Health AS til det brasilianske selskapet Biorigin. Salgssummen er avtalt til 37,5 m...
